Groundbreaking collaboration harnesses AI-driven insights and advanced manufacturing to create next-generation adjuvants for emerging biological threats
PAT after MI is Rs. 41 crore which is 162% increase
The Emcure Research Centre (ERC) will drive research across multiple dosage forms, including OSD, injectables, novel drug delivery systems (NDDS), inhalers and topical and transdermal formulations
The revenue from operations in Q3 FY25 is Rs. 8,358.6 crore, up 16% YoY
Hyper-automated AI is a unified framework combining AI, ML, RPA, and NLQ to streamline data extraction, quality management, transformation, and actionable insights - all on a single platform
This strategic move aims to address the increasing global demand for biologics, enhancing ProBioGen's ability to support partners from cell line development t
Successfully transformed the organization from a two-country operation focused on development and manufacturing to a fully integrated company with a strong commercial engine bringing us closer to patients in over 120 countries
India's bio economy has experienced remarkable growth, skyrocketing from $10 billion in 2014 to over $130 billion in 2024, with projections to reach $300 billion by 2030
Hansoh Pharma has granted Merck an exclusive global license to develop, manufacture and commercialize HS-10535
The technical program will run in four sessions and a panel discussion on “Challenges in translation of medical technologies”
Subscribe To Our Newsletter & Stay Updated
